Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036543 · ClinicalTrials.gov registry record · Phase 3
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
NCT00036543: Completed Phase 3 study, sponsored by Abbott.
NCT00036543 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 1,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036543, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
Interventions
- DRUG Atrasentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2001-05 |
| Phase | Phase 3 |
What the finished NCT00036543 record still lists
NCT00036543 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 1 intervention - of which Atrasentan is the first listed.
NCT00036543 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036543 about?
NCT00036543 is a clinical study titled "A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer". This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
What is the current status of trial NCT00036543?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2001-05.
What interventions are being tested in trial NCT00036543?
The interventions under investigation include: Atrasentan (DRUG).
Who is sponsoring clinical trial NCT00036543?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00036543's enrollment target sits among peer trials
1,000 296th of 2000 higher than 1,689 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia